Poland· PL-100439187

Daurismo

A glasdegib product containing glasdegibum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 10 of our 19 countries.

ATC L01XJ03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDaurismoATCL01XJ03REGISTER NO.PL-100439187PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Glasdegib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01XJ03 (glasdegib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose

Glasdegib · ATC L01XJ03

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Glasdegibum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
L01XJ03
ATC class
Glasdegib
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05415062357385

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

478 interactions on record for glasdegib.

Graded by severity as the source publishes them — 125 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Glasdegib · interactions on record

478 records

  • 125 severe
  • 345 moderate
  • 8 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glasdegib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glasdegib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Daurismo
  • Liechtenstein · Daurismo
  • Norway · Daurismo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee6ce05c-d3a2-427b-b4ec-0ced1995b3de
GET /v1/drugs/ee6ce05c-d3a2-427b-b4ec-0ced1995b3de?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "25 mg",
  "packaging": "05415062357385 ¦ Rpz ¦ EU/1/20/1451/002 ¦ 137234\n60 tabl. w blistrze\nRpz ¦ EU/1/20/1451/001 ¦ 137235\n1 butelka 60 tabl.",
  "substance": "Glasdegibum 25 mg",
  "common_name": "Glasdegibum",
  "pl_product_id": "100439187",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about glasdegib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.